No­var­tis adds In­di­anapo­lis site to its man­u­fac­tur­ing ca­pac­i­ty for ra­di­oli­gand drug Plu­vic­to

No­var­tis has the go-ahead from the FDA to man­u­fac­ture its ra­dio­phar­ma­ceu­ti­cal Plu­vic­to at a new fa­cil­i­ty in In­di­anapo­lis, mark­ing a step to­ward ad­dress­ing bur­geon­ing de­mand.

The Big Phar­ma’s new 70,000-square-foot fa­cil­i­ty is spe­cial­ly de­signed to make ra­di­oli­gand ther­a­pies (RLTs) and, ac­cord­ing to the com­pa­ny, is the largest No­var­tis site of its kind. The fa­cil­i­ty has space for con­tin­ued line ex­pan­sion, in­clud­ing plans for ful­ly au­to­mat­ed lines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER